Stockscreener 앱 받기
0.8497
1.21%
-0.0104
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity - MyChesCo
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotChandelier Stop - vinanet.vn
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined ExecutionEarnings Recovery Stocks - Vinanet
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key SupportStrangle Setup - vinanet.vn
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Mid Cap Momentum - vinanet.vn
Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
APRE: APR-1051 demonstrates promising early efficacy and safety, driving a biomarker-focused oncology pipeline - TradingView
Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks
Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative
Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to earnings forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
Aprea Therapeutics Inc (APRE) Stock News Today - TradingKey
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
Aprea Expands APR-1051 Trial as Enrollment Accelerates - mychesco.com
APRE Q2'26 Earnings: EPS estimate is (0.18) USD - TradingView
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors - TipRanks
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Slide 2.36%High Growth Earnings - dars.gov.et
Aprea Therapeutics plans Q4 2026 data update for APR-1051 trial - Investing.com Nigeria
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 - The Manila Times
Q&A: Aprea Therapeutics' Oren Gilad on WEE1 Inhibitor Data and the Company's DNA Damage Response Strategy - BioPharm International
Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aprea Therapeutics Inc (APRE) Institutional Confidence - TradingKey
APRE|Aprea Therapeutics Inc|Price:0.620|Chg%:-0.012 - TradingKey
Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
APRE|Aprea Therapeutics Inc|Price:0.632|Chg%:+0.004 - TradingKey
Aprea Therapeutics Inc (APRE) Cash Flow - TradingKey
Aprea Therapeutics (NASDAQ: APRE) wins 180-day extension to meet $1 bid - Stock Titan
Aprea Therapeutics (APRE) Edges Higher with Modest Gains Amid Tight Trading RangeMedian Line - dars.gov.et
Aprea Therapeutics(APRE) Stock Options Chain | Quotes & News - Moomoo
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
APRE Forecast — Price Target — Prediction for 2027 - TradingView
Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE) - TradingView
Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics - BioPharm International
Aprea Shareholders Approve Directors, Reverse Split Flexibility - The Globe and Mail
Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting - Minichart
Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2.45%
자본화:
|
볼륨(24시간):